First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis

Sanet Torres-Torres, Angela L. Myers, J. Michael Klatte, Eric E. Rhoden, M. Steven Oberste, Marc S. Collett, Russell J. McCulloh

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.

Original languageEnglish (US)
Pages (from-to)52-54
Number of pages3
JournalPediatric Infectious Disease Journal
Volume34
Issue number1
DOIs
StatePublished - Jan 1 2015

Keywords

  • Coxsackievirus
  • Neonatal enterovirus infection
  • Pocapavir

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis'. Together they form a unique fingerprint.

  • Cite this